Generation of hematopoietic stem/progenitor cells with sickle cell mutation from induced pluripotent stem cell in serum-free system

Author(s)

Paes, Barbara C. M. F. ^{[1, 2]} ; Stabeli, Luiza C. J. R. ^{[1, 2]} ; Costa, Pericles N. M. ^[2] ; Orellana, Maristela Delgado ^[2] ; Kashima, Simone ^[2] ; Covas, Dimas Tadeu ^{[1, 2]} ; Picanco-Castro, Virginia ^{[1, 2]}

Affiliation

^[1] Univ Sao Paulo, Fac Med Ribeirao Preto, Ribeirao Preto, SP - Brazil

^[2] Univ Sao Paulo, Hemoctr Ribeirao Preto, Ctr Terapia Celular, Ribeirao Preto, SP - Brazil

• Document type: Journal article
• Source: Hematology, Transfusion and Cell Therapy; v. 43, n. 2, p. 156-164, APR-JUN 2021.
• Web of Science Citations: 1

Abstract

Introduction: Sickle cell disease (SCD) is a monogenic disease and it is estimated that 300,000 infants are born annually with it. Most treatments available are only palliative, whereas the allogeneic hematopoietic stem cell transplantation offers the only potential cure for SCD. Objective: Generation of human autologous cells, when coupled with induced pluripotent stem cell (iPSC) technology, is a promising approach for developing study models. In this study, we provide a simple and efficient model for generating hematopoietic cells using iPSCs derived from a sickle cell anemia patient and an inexpensive in-house-prepared medium. Method: This study used iPSCs previously generated from peripheral blood mononuclear cells (PBMCs) from a patient with sickle cell anemia (iPSC scd). Hematopoietic and erythroid differentiation was performed in two steps. Firstly, with the induction of hematopoietic differentiation through embryoid body formation, we evaluated the efficiency of two serum free media; and secondly, the induction of hematopoietic stem/progenitor cells to erythroid progenitor cells was performed. Results: The patient-specific cell line generated CD34(+)/CD45(+) and CD45(+)/CD43(+) hematopoietic stem/progenitor cells and erythroid progenitors, comprising CD36(+), CD71(+) and CD235a(+) populations, as well as the formation of hematopoietic colonies, including erythroid colonies, in culture in a semi-solid medium. Conclusion: In conjunction, our results described a simple serum-free platform to differentiate human the iPSCs into hematopoietic progenitor cells. This platform is an emerging application of iPSCs in vitro disease modeling, which can significantly improve the search for new pharmacological drugs for sickle cell disease. (C) 2020 Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. (AU)

• FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
• Grantee: Dimas Tadeu Covas
• Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC